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Regulation of Chondrogenesis in Human Mesenchymal Stem Cells  
by Cartilage Extracellular Matrix and Therapeutic Applications 
Ang Li 
 
 Cartilage has limited intrinsic healing potential upon injury, due to the low cell density 
and the lack of blood supply. Degenerative disease of the cartilage, such as osteoarthritis (OA), is 
challenging to treat without clear mechanistic understandings of cartilage development. With 
over 90% of the cartilage tissue occupied by extracellular matrix (ECM), understanding the 
cellular and molecular effects of cartilage ECM on chondrogenesis and chondrocyte behavior is 
crucial for therapeutic development. The focus of this work is to study the regulation of 
chondrogenesis and hypertrophic maturation of human mesenchymal stem cells (MSCs) by 
cartilage ECM in the context of potential therapeutic applications. 
 To study the cartilage ECM, we created a decellularized ECM digest from native porcine 
cartilage and examined its effects on MSCs. Since native cartilage ECM maintains chondrocyte 
homeostasis without progressing to hypertrophic degeneration, we hypothesized that the 
decellularized ECM would promote MSC chondrogenesis and inhibit hypertrophy. Indeed, we 
showed that ECM promoted MSC chondrogenesis and matrix production, and inhibited 
hypertrophy and endochondral ossification. The chondrogenic effect was shown to potentially 
involve the PI3K-Akt-Foxo1 and Hif1 pathways. By recapitulating the activated Hif1 pathway, 
roxadustat, a small molecule stabilizer of Hif, was able to reproduce the chondrogenic and anti-





metalloproteases (MMPs) in MSCs, healthy chondrocytes, and OA chondrocytes, and alleviated 
matrix degradation in bovine cartilage explants.  
 We also attempted to identify ECM components that display chondrogenic properties. 
Collagen XI, a minor component of articular cartilage, was shown to promote cartilage matrix 
formation in MSCs and healthy chondrocytes, and to reduce matrix degradation in bovine 
cartilage explants. 
 Taken together, this study reveals the dual roles of cartilage ECM in promoting 
chondrogenesis and matrix production and inhibiting cartilage hypertrophy. Importantly, small 
molecule drugs that recapitulate the signaling pathways of ECM regulation, and collagen XI, a 
component of the ECM, may serve as leads for further therapeutic development for cartilage 
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Chapter 1. Introduction 
 Cartilage is a connective tissue consisting of a rich extracellular matrix (ECM) and one 
major cell type, chondrocytes. Due to the lack of blood supply and sparse cell distribution, 
cartilage is difficult to heal upon injury and under degenerative processes.  
In 2014, over 850,000 cartilage repair procedures were conducted in the US alone 
(Vericel Presentation, 2017). Non-surgical procedures include lavage, shaving, debridement, 
abrasion chondroplasty, Pridie drilling, microfracture, and spongilization (Van Manen et al., 
2012). Surgical approaches include osteotomy, which involves cutting bone for realignment or 
mechanical load re-distribution, and distraction of joints (Van Manen et al., 2012). Another class 
of therapy centers on implantation of allogeneic or autologous cartilage tissue (Van Manen et al., 
2012). However, these strategies do not fully restore damaged cartilage.  
An estimated 27 million of US population has clinical osteoarthritis (OA) in the knee, hip, 
hand, and shoulder (Lawrence et al., 2008). OA is manifested with degradation and loss of 
articular cartilage, coupled with low-grade inflammation. Existing pharmacological treatments 
mainly address the pain and inflammation involved in the joints, with no disease-modifying 
therapy that stops disease progression. Once pharmacological options are exhausted, surgery 
such as knee or hip replacement serves as the last resort. 
Due to the serious unmet need in cartilage diseases, understanding the differentiation, 
growth, and maintenance of cartilage is crucial for new drug development. With the 





and cells, we sought to solve these clinical problems by studying how ECM regulates cartilage 
cells. 
ECM, the native scaffolding material secreted and maintained by resident cells, provides 
an ideal microenvironment for cells, with tissue-specific physical and molecular cues mediating 
cell proliferation, differentiation, gene expression, migration, orientation, and assembly (O’Neill 
et al., 2013). Functional and structural components within the ECM contribute to the 
extracellular environment specific to each tissue and organ. The complexity of the ECM has 
proven difficult to recapitulate in its entirety, with attempts often limited to mimicking only 
ECM structure using synthetic biomaterials or mimicking composition by adding purified ECM 
components (O’Neill et al., 2013). To address this limitation, we used a decellularized digest of 
whole cartilage ECM, which should preserve the majority of the ECM materials, and studied its 
effect on various cell types involved in cartilage diseases and repair. 
Chapter 2 presents an overview of the existing knowledge on chondrogenic 
differentiation in vitro and in vivo, the role of cartilage ECM, and the signaling mechanisms 
involved in chondrocyte regulation. Chapter 3 describes the studies on ECM regulation of MSC 
chondrogenesis and hypertrophy. In chapter 4, we identified potential signaling pathways 
involved in ECM regulation and novel chondrogenic components. Chapter 5 shows the 
chondrogenic effects of roxadustat, a small molecule Hif stabilizer that potentially recapitulates 
the signaling mechanisms of the ECM. Chapter 6 summarizes the findings and discusses their 
values for developing new drugs for cartilage injury and osteoarthritis.  
Overall, by studying cartilage ECM, we explored a new dimension in the regulation of 
cartilage cells in their growth and differentiation. This novel approach may point to new 






Chapter 2. Background 
 Cartilage consists of a preponderance of ECM and chondrocytes. The ECM is composed 
of complex macromolecules organized in 3D network forming a gel-like material and its 
function is to resist mechanical loading. Compositions of the ECM include collagen II, collagen I, 
and glycosaminoglycans (GAGs), among others (Gao et al., 2014). Together, they create a 
hydrophilic environment, which enables cartilage tissue to exhibit swelling pressure, countered 
by tensile strength generated from collagen network (Gao et al., 2014). These mechanical 
properties of cartilage allow it to withstand pressure at articular joints. Upon traumatic injury or 
degeneration, changes in the biochemical compositions in the cartilage lead to decreased 
mechanical strength, which causes physical disabilities, inflammation, and pain. 
 The three main subtypes of cartilage each exhibit their own compositional and structural 
properties. The hyaline cartilage, found at articular joints and the nucleus pulposus in the 
intervertebral discs, is rich in collagen II and GAGs, thus demonstrating the highest Young’s 
modulus (Benjamin and Ralphs, 2004). The fibrocartilage, found at the meniscus and the 
annulus fibrosus in the intervertebral discs, consists of collagen I fibers, in addition to collagen II 
and GAGs. The fibrocartilage is inferior to hyaline cartilage in terms of withstanding weight, but 
it serves other important structural roles. The elastic cartilage, found in the ears and part of 
larynx, contains elastic fibers and is not the focus of this work. 
 To treat cartilage diseases, it is desired to return the diseased cartilage to their healthy 
biochemical and mechanical state. In cartilage diseases, a lack of ECM or a diseased ECM may 





healthy ECM or alternative factors that mimic the ECM signal is a potential therapeutic strategy 
for cartilage diseases. 
2.1 Overview of cartilage differentiation and development 
2.1.1     Cartilage development in vivo 
During long bone development, cartilage forms via condensations of mesenchymal cells, 
which give rise to cartilage primordia consisting of immature chondrocytes (Figure 1) 
(Kozhemyakina et al., 2015). Proliferating chondrocytes form orderly parallel columns in the 
growth plate, and are characterized by the expression of type II collagen and proteoglycans such 
as aggrecan (Michigami, 2014). When chondrocytes mature, they become hypertrophic and 
begin to produce a high level of alkaline phosphatase and type X collagen. Eventually, the 
terminally differentiated chondrocytes undergo apoptosis, and the cartilaginous matrix is 
mineralized and replaced by bone. A small portion of cartilage remains at both ends of the bone 
and becomes articular cartilage. 
 





2.1.2     Chondrogenic differentiation in vitro 
In vitro, chondrogenesis is recapitulated by condensing bone-marrow-derived MSCs and 
culturing in the presence of chondrogenic factors such as TGF β3 and IGF (Bhumiratana et al., 
2014). These condensed pellets undergo chondrogenic differentiation by expressing markers 
such as Sox9 and producing matrix materials including proteoglycans and type II collagen. After 
two to five weeks of chondrogenic induction, these pellets start to undergo hypertrophic 
maturation spontaneously, marked by the expression of type X collagen. Alternatively, 
hypertrophic differentiation can be induced by the removal of TGF β3 and the addition of L-
thyroxine (T4) and β-glycerophosphate to the culture (Ng et al., 2017). During three weeks of 
hypertrophic induction, cell pellets degrade cartilage matrix components such as GAG and 
collage II, produce new matrix such as collagen X, and form calcium mineral depositions, 
marker of endochondral ossification. 
2.2 Biological functions of extracellular matrix 
ECM is a three-dimensional, non-cellular structure that is present in all tissues (Bonnans 
et al., 2014). Every organ has an ECM with a unique composition that is generated in early 
embryonic stages. The function of the ECM goes beyond providing physical support for tissue 
integrity and elasticity: it is a dynamic structure that is constantly remodeled to control tissue 
homeostatsis. In mammals, the ECM is composed of around 300 proteins, known as the core 
matrisome, and includes proteins such as collagen, proteoglycans, and glycoproteins (Hynes et 
al., 2012). The ECM can also sequester and locally release growth factors, such as epidermal 
growth factor, fibroblast growth factor, and other signaling molecules such as Wnts (Hynes et al., 
2012). ECM components released through ECM cleavage also regulate ECM architecture and 





through synthesis, degradation, reassembly, and chemical modification (Hynes et al., 2012). 
These processes are complex and need to be tightly regulated to maintain tissue homeostasis, 
especially in response to injury. Indeed, deregulated ECM remodeling is associated with 
pathological conditions and can exacerbate disease progression. 
The cartilage ECM, specifically, is composed of large proteoglycans that contain GAG, 
hyaluronic acid (HA), fibers, and other molecular components such as fibronectin and laminin 
(Figure 2) (Heinegard and Saxne, 2011). Fibers contain elastin and collagens that include 
fibrillary collagen (types I, II, III, V and XI), fibril-associated collagen with interrupted triple 
helices (FACIT) (types IX, XII, and XIV), short chain collagen (types VIII and X), basement 
membrane collagen (type IV), and others (types VI, VII, and XIII). In the ECM, especially the 
basement membrane, the multidomain proteins perlecan, agrin, and collagen XVIII are the main 
proteins to which heparin sulfate attaches. At last, there are important molecular components 
called integrins, which are transmembrane receptors that mediate the attachment between a cell 
and its surroundings. Furthermore, signaling factors are also present in the cartilage ECM. By 
proteomic comparison between OA and normal cartilage samples, TGF β1 is found in normal 
human cartilage (Wu et al., 2007). From decellularized pig ear cartilage, TGF β1, IGF-1, and 
BMP-2 were found by chemical extraction (Xue et al., 2012). From decellularized bovine inner 
and outer menisci, different levels of FGF-2, EGFR, insulin, and TGF β1/3 were discovered 






Figure 2. The molecular organization of normal articular cartilage (Heinegard and Saxne, 2011). 
Articular cartilage ECM plays a crucial role in regulating chondrocyte functions. The 
ECM has a significant effect on the swelling behavior and osmotic environment of chondrocytes 
(Gao et al., 2014). Cell signaling mediated by integrin regulates several chondrocyte functions, 
including differentiation, matrix remodeling, responses to mechanical stimulation, and cell 
survival. For example, MSCs growing on the surface of cartilage ECM hydrogels have been 
shown to express increased levels of chondrogenic genes without additional chondrogenic 
stimulation (Burnsed et al., 2016). Decellularized cartilage particles, when mixed with MSCs, 
also promote proliferation and chondrogenic gene expression in the absence of other stimulations 
(Sutherland et al., 2015). Decellularized cartilage sheets with MSCs seeded on the surface 





implantation (Xue et al., 2012). In addition, ECM scaffolds produced by cultured chondrocytes 
accelerate chondrogenic differentiation in vitro, maintain better cartilage phenotype, and inhibit 
hypertrophic mineralization in vivo compared to a PGA scaffold (Choi et al., 2010). Furthermore, 
cartilage fragments from OA knee mixed with MSCs show neocartilage structures and increased 
collagen type II expression in a subcutaneous environment in mice (Chen et al., 2011). Taken 
together, these findings support a biological role of cartilage ECM in promoting chondrogenesis 
and inhibiting hypertrophic maturation. 
To analyze the mechanisms behind the effects of cartilage ECM, different components of 
the ECM have been studied for their chondrogenic activities. MSCs seeded on the surface of 
alginate microbeads have increased chondrogenesis when the microbeads are pre-coated with 
chondroitin sulfate (CS) or collagen II, increased hypertrophic maturation with collagen II 
coating, but decreased hypertrophy with CS coating (Wu et al., 2007). Consistently, a composite 
PEG-CS hydrogel increased chondrogenic markers and matrix production but inhibited 
spontaneous hypertrophic maturation (Varghese et al., 2008). In a methacrylated HA hydrogel, 
collagen I and CS were all shown to increase GAG accumulation in vitro and in vivo, and 
decrease hypertrophic markers (Zhu et al., 2016). In addition, cartilage oligometric matrix 
protein (COMP) plays an important role in cartilage cell-matrix interactions. COMP induced the 
survival of the inhibitor of apoptosis family of proteins to lead to strong inhibition of 
chondrocyte apoptosis by blocking the activation of caspase 3 (Gao et al., 2014). These studies 
suggest that various components of the ECM may have different or even opposing roles in 







2.3 Signaling mechanisms involved in chondrogenesis and chondrocyte hypertrophy 
The differential gene expression profile during chondrogenesis and hypertrophic 
maturation is summarized in figure 3 (Kozhemyakina et al., 2015) and figure 4 (Zhong et al., 
2015). Briefly, mesenchymal condensation induces the expression of Sox 5/6/9, which then 
activates the expression of chondrogenic markers including aggrecan and collagen II. The 
expression of Sox9 can be modulated by TGF β, BMPs, Wnt signaling, FGF 9/18, PTHrP, IGF-1, 
and CNP, among others. During hypertrophy, Runx2 expression is activated to drive the 
expression of markers including VEGF, MMP13, collagen X, and IHH. The expression of Runx2 
is regulated by FGF2, BMP, Wnt signaling, IHH, IGF-1, and CNP, among others. 
 
Figure 3. Chondrogenic and hypertrophic gene expression at different stages of chondrocyte 






Figure 4. Differential signaling pathways in normal chondrocytes and hypertrophic chondrocytes 
(Zhong et al., 2015). 
2.3.1 Hif pathway 
Cartilage is a hypoxic tissue and chondrocytes were shown to respond to hypoxia by 





Under normoxia, the prolyl hydroxylase domain (PHD) hydroxylates Hif α (hypoxia-inducible 
factor α) and targets it for ubiquitination and degradation (Maes et al., 2012). Under hypoxia, 
however, the PHD senses the low oxygen level, and stabilizes Hif α, which then enters the 
nucleus to initiate transcriptional activities (Figure 5). Hypoxia promotes rat MSC 
chondrogenesis via Hif1α stabilization and phosphorylation of Akt (Kanichi et al., 2008). 
Activation of Hif1α by flavonoid promotes chondrocyte proliferation and cartilage matrix 
production, and further promotes articular cartilage repair in a mouse model (Wang et al., 2016). 
Hif1α is overexpressed in human OA cartilage and under catabolic stress such as hydrogen 
peroxide and IL-1β (Yudoh et al., 2005). 
 
Figure 5. The Hif pathway (Maes et al., 2012). 
 In contrast, Hif2α promotes cartilage hypertrophy and endochondral ossification, MMP 
production, and apoptosis (Zhang et al., 2015). Hif2α potently binds to the promoter region of 
Col10A1, MMP13, and VEGFA, and is essential for endochondral ossification of culture 
chondrocytes independent of hypoxia (Saito et al., 2010). Furthermore, Hif2α mediates the IL-
1β-induced expression of catabolic factors in rabbit chondrocytes, including MMPs, ADAMTS4, 





2010). Consistently, heterozygous deletion of Hif2α showed suppressed cartilage destruction in 
mouse OA models. These results suggest a potential chondro-protective role of Hif1 and 
destructive role of Hif2. As a result, a fine balance between Hif1 and Hif2 may be essential for 
cartilage homeostasis. 
2.3.2 PI3K-Akt-Foxo1 pathway 
The PI3K-Akt-Foxo1 pathway is also involved in cartilage development (Figure 6) 
(Wimmer et al., 2014). In this pathway, an extracellular ligand activates a cell surface receptor, 
which activates phosphatidylinositol 3-kinase (PI3K). PI3K phosphorylates and activates Akt, 
which further phosphorylates Foxo1 in the cytoplasm. Foxo1 is a transcription factor that is 
active in the nucleus but inactive in the cytoplasm. By phosphorylating Foxo1, p-Akt targets p-
Foxo1 for degradation.  
In MSC pellet cultures, Lee et al. (2013) showed that hypoxia enhances chondrogenesis 
and prevents terminal differentiation through the PI3K/Akt/Foxo1 pathway. PI3K-Akt is also a 
downstream mediator for Sox9-induced chondrocyte survival and hypertrophy (Ikegami et al., 
2011). Inversely, PI3K-Akt also maintains Sox9 gene expression and activity as a transcription 
factor for aggrecan in nucleus pulposus cells of the intervertebral discs (Cheng et al., 2009). 
PI3K/Akt is a downstream mediator of IFG2 in chondrogenesis (Hamamura et al., 2008), and 
Akt is a downstream mediator of TGFβ in mouse precartilaginous stem cells (Cheng et al., 2014). 
In the case of hypertrophy, PI3K promotes hypertrophic chondrocyte differentiation and 
survival in mouse tibial organ cultures (Ulici et al., 2008), but Kita et al. (2008) showed an 
inhibitory role of PI3K/Akt in hypertrophic differentiation in mouse forelimb organ cultures. 






Figure 6. The PI3K-Akt-Foxo1 pathway (Wimmer et al., 2014). 
 As for Foxo, Shen et al. (2015) showed that Akt/Foxo3 protects chondrocyte from 
apoptosis via autophagy. In human and mouse OA cartilage, Foxo is strongly phosphorylated 
and localized in the cytoplasm (Akasaki et al., 2014). Foxo1 and Foxo3 knockout mice show 
severe growth plate abnormalities, including excessive cartilage protruding into the mineralized 
bone at the chondro-osseus junction of the long bones, and increased length of hypertrophic 
chondrocyte zone (Eelen et al., 2016). The above findings on PI3K/Akt/Foxo1 suggest important 
roles for this pathway in regulating chondrogenesis and hypertrophy. 
2.4 Pathophysiology of cartilage injury and degenerative disease 
2.4.1     Pathophysiology of cartilage injury 
Articular cartilage lesions represent one of the major unsolved problems in orthopedic 
surgery due to the limited capacity of articular cartilage for self-repair following trauma (Peretti 
et al., 2011). The biological response of cartilage to injury varies depending on the extent of the 
trauma. When a lesion is confined to the superficial layer, the repair process is not initiated, as 
the inflammatory stimulus is too weak to stimulate the resident chondrocytes surrounding the 





However, when a full-thickness lesion occurs, reaching the vessels of the subchondral 
bone, the inflammatory stimulus is more important (Peretti et al., 2011). Bleeding from the bone 
marrow occurs, allowing the access of growth factors and reparative cells to the lesion site. 
These cells are mainly fibroblasts in addition to a low percentage of mesenchymal stem cells. As 
a result, the newly formed reparative tissue is richer in collagen I and structurally weaker than 
native hyaline cartilage. Notably, if the full-thickness lesion is left untreated, it may increase in 
size over time and induce concomitant changes of the underlying subchondral bone plate and 
bone overgrowth or bone loss. As such, it has the potential to contribute to the initiation and 
development of osteoarthritis. Therefore, the treatment goal of osteochondral cartilage defects 
should be to restore the physiological properties of the entire osteochondral unit, aiming to 
achieve a more predictable repair tissue that closely resembles the native articular surface and 
remains durable over time.  
2.4.3 Pathophysiology of osteoarthritis 
Osteoarthritis is a chronic, inflammatory, and degenerative joint disease. Characterized 
by pain, stiffness, muscle weakness, and bone swelling, it involves the entire joint including 
articular cartilage, subchondral bone, and the synovium (Ashkavand et al., 2013). The common 
features of OA are loss of cartilage, joint space narrowing, hypertrophic bone changes, 
osteophyte formation, and subchondral bone sclerosis (Figure 7) (Yuan et al., 2014). In end-
stage OA, there is near complete loss of articular cartilage and the joint has to be replaced by 
surgery. 
The exact cause of OA is unknown, but risk factors include advanced age, female gender, 
genetics, carbohydrate-rich diet, joint injury and trauma, and obesity, among others (Ashkavand 





show increased metabolic activities and release of factors such as nitrite oxide, reactive oxygen 
species (ROS), alarmins, pro-inflammatory cytokines, and chemokines. The subchondral bone 
shows increased cortical bone porosity and cortical plate remodeling. As the disease progresses, 
there is loss of proteoglycans and disruption of the collagen network in the cartilage, increased 
cortical plate thickness, and decreased subchondral bone mass and altered architecture. In the 
next stage, the cartilage matrix fragments into fissures, accompanied by formation of bone cysts 
and osteophytes. In late-stage OA, chondrocytes undergo hypertrophic changes and apoptosis. 
The calcified cartilage expands into the articular cartilage and becomes vascularized and 
innervated. There is new bone formation at the osteochondral junction as well as disruption of 
the osteocyte canalicular network. 
 
Figure 7. Differences between normal and osteoarthritis joints (Yuan et al., 2014).  
On the molecular level, articular chondrocytes express lower levels of cartilage markers 





Runx2 and collagen X (Ashkavand et al., 2013). Degradation of the cartilage matrix is driven 
mainly by MMP1/3/13 and ADAMT 4/5, which, in turn, are regulated by inflammatory factors 
such as IL1/6 and NF-κB. These processes are further under the regulation of factors such as 



















Chapter 3. Determine the effects of cartilage extracellular matrix on chondrogenesis and 
hypertrophy in human MSCs 
3.1 Abstract 
Decellularized cartilage ECM preserved the biochemical composition of native cartilage. 
ECM supplementation in culture medium promoted MSC proliferation, chondrogenic 
differentiation, and cartilage matrix production. This effect was dose-dependent and long-lasting, 
and was most effective during early chondrogenesis. ECM also increased maturity of 
chondrogenesis and directed MSCs towards a hyaline-like phenotype. In addition, ECM delayed 
hypertrophy and endochondral ossification in MSC-derived chondrocytes. 
3.2 Background 
The cartilage extracellular matrix (ECM) maintains the chondrocyte phenotype and 
cartilage homeostasis in healthy tissues. In degenerative diseases such as osteoarthritis (OA), the 
loss and altered compositions of the ECM may contribute to the downward spiral of disease 
progression. Various components of the ECM have been shown to modulate MSC 
chondrogenesis and hypertrophy both in vitro and in vivo, including GAGs, collagen II, and 
hyaluronic acid, among others. However, how these various ECM components interact with each 
other to regulate cartilage homeostasis and the effect of the ECM as a whole on chondrogenesis 
is unknown. Since it is essentially impossible to recreate the ECM synthetically by mixing 
various components together, here we used a decellularized and digested formulation of whole 
native cartilage ECM to study its effects. This section focuses on the effects of ECM on the 






Firstly, we characterized the biochemical contents and biological effects of decellularized 
cartilage ECM. The ECM digest can be used in different formats such as culture media 
supplement, hydrogel, and solid sheet (O’Neill et al., 2013). Composition of the native ECM 
changes during processing, and maximum preservation of the biochemical compositions of the 
native tissue is desired. To this end, key ECM components at different stages of processing was 
analyzed. Also, the effects of the ECM on MSC proliferation and metabolism were quantified. 
Secondly, the effects of ECM on MSC chondrogenesis were analyzed by using it as cell 
culture supplements. MSC pellets were cultured in chondrogenic media in the presence or 
absence of ECM supplements for 5 weeks and biochemical compositions and cartilage gene 
expression were compared. A dose response of ECM supplementation (from 0.05mg/ml to 
0.2mg/ml) on matrix production was established, and the effects of timing (during early, mid, or 
late chondrogenesis) of ECM supplementation on matrix production was studied. These studies 
aimed to test the hypothesis that cartilage ECM promotes MSC chondrogenesis. 
Since native ECM maintains chondrocytes in a stable phenotype without progressing to 
hypertrophy, as seen in osteoarthritis, we asked whether ECM can inhibit chondrocyte 
hypertrophy. To address this question, ECM supplement (0.1mg/ml) was provided during the 
chondrogenic and/or hypertrophic culture of MSCs, and biochemical compositions, 
chondrogenic/hypertrophic gene expression, and mineral depositions over the 5-week culture 
period were analyzed. Furthermore, a dose response of ECM supplementation (from 0.05mg/ml 
to 0.2mg/ml) on mineral depositions in MSC pellets was established, and the durability of the 







3.3.1     Preparation of decellularized cartilage ECM 
Native porcine tracheal cartilage was obtained from Green Village Packing (Green 
Village, NJ). The tissue was lyophilized and mechanically broken into small pieces with mortar 
and pestle. Using an orbital shaker (120rpm), lyophilized tissue was washed three times using 
6.7ml of water and 2X PBS per gram of tissue,  treated with 0.02% trypsin at 37oC for 2 hours, 
and again washed with 6.7ml of water and 2X PBS per gram tissue. The tissue was 
decellularized with 40g/L of deoxycholic acid in water overnight, and washed with 6.7ml water 
and 2X PBS. It was then treated with 50U/ml DNase I overnight, and washed with water and 2X 
PBS. The decellularized tissue was sterilized with 0.1% peracetic acid and washed thoroughly 
with sterile water. All chemicals were from Sigma (St. Louis, MO). 
The sterile decellularized tissue was digested with pepsin. For 1g of lyophilized ECM, 
0.1g pepsin in 100 ml sterile 0.01M HCl were used. The digestion occurred at 37oC shaking with 
frequent monitoring. The final digest should be a thick milky liquid with a small portion of 
undigested pieces. Excessive digestion that resulted in a watery liquid was avoided. This would 
result in a digested ECM concentration of 10mg/ml, which could be further made into hydrogel, 
liquid supplement to media, and plate coating. 
3.3.2 Biochemical assays 
Cell monolayers or pellets (containing at most 10 million cells) were digested in 1ml of 
papain at 65oC overnight to yield a homogeneous solution. Briefly, the composition of the papain 





pH=6.0. Each milliliter of papain digestion buffer was mixed with 20μl of papain (Sigma) before 
use.  
DNA quantification was conducted with PicoGreen assay (Fisher, Hampton, NH). 100μl 
of sample digest (n=4) were added to the wells of black plates. Then, a 1:200 dilution of the 
PicoGreen reagent was added to each well and read on a fluorescent microplate reader 
(Excitation: 485nm, Emission: 520nm). 
For GAG quantification, 40μl of sample digest (n=4) and chondroitin-6-sulfate standards 
were added to the wells of clear plates. 200μl of DMB dye was added to the wells immediately 
before absorbance reading at 540nm and 595nm. The difference between two readings correlate 
with GAG quantity. DMB dye was prepared by 980ml of mixing solution A (2g/ml sodium 
formate, 2ml/ml formic acid, pH=3.5) and 5ml solution B (16mg of 1,9 dimethylene blue (DMB) 
(Sigma) in ethanol) and adjusted to 1L by water. 
For hydroxyproline (OHP) quantification, 500μl of the sample digest was mixed with 
500μl 12M HCl and heated to a dry char at 110oC overnight. The char was resuspended in 1ml of 
assay buffer. 100μl of each sample was added to the wells of a clear plate, and 50μl of 
chloramine T reagent was added, mixed, and let sit for 20 minutes at room temperature. Then, 
50μl of dimethylaminobenzaldehyde reagent was added and mixed in each well. The plate was 
incubated at 60oC for 15 minutes and read at absorbance of 540nm. For this assay, the stock 
buffer contained 50g/L of citric acid monohydrate, 12ml/L glacial acetic acid, 120g/L sodium 
acetate trihydrate, and 34g/L sodium hydroxide at pH=6.0. The assay buffer was prepared by 
1:10 dilution of stock buffer. Chloramine T reagent contained 70.5mg of chromamine T, 1.035ml 





contained 0.75g of p-dimethylaminobenzaldehyde (Sigma) dissolved in 3ml 1-propanol and 
1.3ml perchloric acid. 
3.3.3 Preparation of ECM/collagen hydrogel 
Decellularized cartilage ECM from porcine trachea was obtained from East River 
Biosolutions (New York, NY). Bovine collagen I solution was obtained from Life Technologies 
(A10644-01, Carlsbad, CA). To make a 6mg/ml hydrogel, 60μl of cold 0.1M NaOH, 67μl of 
cold 10X PBS, 273μl of cold 1X PBS, and 600μl of cold ECM digest (at 10mg/ml) were 
sequentially added. pH was adjusted to 6.5-7.5. 300μl of hydrogel was added to a 48-well plate 
and incubated at 37oC for 45 minutes for gelation. MSCs were seeded onto the surface of the 
hydrogel. 
3.3.4 Preparation of ECM/collagen coating 
200μl of ECM or collagen type I at a concentration of 2mg/ml was added to 48-well 
plates and let dry overnight. After complete drying, the wells were washed twice with PBS to 
remove any particulates.  
3.3.5 MTT assay for measuring cellular metabolic activity 
MSCs were seeded into 48-well plate that were either uncoated or coated with hydrogel 
described in 3.3.3 at 20,000 cells/cm2, and cultured in high glucose DMEM with 10% FBS for 48 
hours. After the 48-hour incubation, the culture media were replaced with media containing 10% 
Alamar Blue (Promega, G808A, Madison, WI). After 14-hour incubation, media was transferred 






3.3.6 Culture regimens for studying chondrogenesis and hypertrophy 
MSCs (P5), normal adult chondrocytes (P6) (Cell Applications), and osteoarthritic adult 
chondrocytes (P6) (Cell Applications, San Diego, CA) were expanded in DMEM (Fisher) with 
10% FBS and Pen-Strep. For chondrogenic differentiation, 200,000 cells were centrifuged to 
form a pellet at 300g for 5 minutes in 96-well deep-well plates (Fisher), and cultured in 
chondrogenic media for 2-5 weeks. Chondrogenic medium contained 476ml of high-glucose 
DMEM, 0.1μM dexamethasone, 50μg/ml L-proline, 5ml sodium pyruvate (Life Technologies), 
5ml ITS+ (Corning, Corning, NY), 5ml HEPES (Life Technologies), fresh dosage of 50μg/ml 
ascorbic acid, and fresh dosage of 10ng/ml TGF-β3 (Peprotech, Rocky Hill, NJ).  
For hypertrophic differentiation, cells were incubated in chondrogenic medium for 2-4 
weeks before cultivation in hypertrophic medium for 3 weeks. The hypertrophic medium 
contained 476ml of high-glucose DMEM, 0.1μM dexamethasone, 50μg/ml L-proline, 5ml 
sodium pyruvate, 5ml ITS+, 5ml HEPES, 5mM sodium beta-glycerophosphate (Sigma), fresh 
dosage of 50μg/ml ascorbic acid, and fresh dosage of 50ng/ml L-thyroxine T4. 
3.3.7 qPCR analysis of gene expression 
RNA was isolated with Trizol extraction (Life Technologies), cleaned with a DNase I kit 
(Invitrogen, Carlsbad, CA), and made into cDNA (Applied Biosystems, Foster City, CA). 
Quantitative PCR was conducted with a SYBR Green qPCR kit (Applied Biosystems) in a 







3.3.8 Histology and immunohistochemistry 
Cell pellets were fixed in 10% formalin and embedded in paraffin. For Alcian Blue 
staining, the slides were stained in Alcian Blue solution (0.1g Alcian Blue in 9ml water and 1ml 
1M HCl) for 5 minutes, before washed thoroughly with acid alcohol (0.12M HCl in 70% EtOH). 
For Alizarin Red staining, the slides were stained in Alizarin Red solution (2g Alizarin Red in 
100ml water, pH=4.1-4.3) for 30 seconds to 5 minutes, before wash in water.  
Immunostaining with collagen I (Abcam 6308, 1:200, Cambridge, UK), collagen II 
(Abcam 34712, 1:200), and collagen X (Abcam 49945, 1:2000) were conducted with Vectastain 
Elite ABC HRP Kit (Vector Lab, Burlingame, CA) and DAB Staining Kit (Vector Lab). For 
collagen I and II staining, slides were incubated in 0.05% trypsin at 37oC for 15 minutes and 0.3% 
H2O2 in methanol for 30 minutes. For collagen X staining, slides were incubated in 
hyaluronidase (2mg/ml in PBS, Sigma) at 37oC for 60 minutes, and Pronase E (1mg/ml in PBS, 
Sigma) at 37oC for 60 minutes. Images were acquired with Olympus FSX-100 microscope 
(Olympus, Center Valley, PA). 
3.3.9 Calcium quantification assay 
Cell pellets were shaken in 1ml 5% trichloroacetic acid at room temperature overnight. 
Calcium was dissolved and quantified with a Stanbio Total Calcium LiquiColor Kit (Stanbio, 
Boerne, TX). 
3.3.10 Micro-CT analysis 
For micro-CT, cell pellets were fixed in 10% formalin overnight and kept in PBS. Three-
dimensional high-resolution images were obtained using a micro-CT system (VivaCT 40; 





global threshold. Standard morphological parameters such as mineral volume and mineral 
density were evaluated for each sample using the standard morphological analysis software on 
the VivaCT 40 system.  
3.3.11 Statistical analysis 
Statistics were performed with GraphPad Prism 6.0. Data were expressed as the average 
+/- standard deviation of n=4-6 samples per group and time point. The differences between 
groups were examined by analysis of variance with an alpha level of 0.05. p<0.05 *, p<0.01 **, 
p<0.001 ***, p<0.0001 ****. For comparison between two groups, Student’s t-test was used. 
For comparison between multiple groups at a single time point, one-way ANOVA with Tukey’s 
post hoc test was used. For comparison between multiple groups at multiple time points, two-
way ANOVA with Bonferroni post hoc test was used. In general, key experiments were 
conducted with ECM isolated from two pigs and MSCs from two human donors, and replicated 
in at least two independent experiments. 
3.4 Results 
3.4.1 Biochemical characterization of decellularized cartilage ECM 
Native porcine tracheal cartilage was prepared in sequential steps and different 
preparations were used in different format of cell assays (Figure 8). Briefly, native cartilage was 
decellularized and digested to form a thick milky liquid with suspended particulates, which were 
small pieces of partially digested ECM. After removing the particulates by filtration through a 
100μm strainer, the liquid fraction of the ECM was used as culture medium supplement or to 







Figure 8. Stages in the preparation of cartilage ECM. 
 During decellularization, over 90% of the DNA content was removed from the ECM 
(Figure 9A). GAG was partially preserved and collagen was fully preserved (Figure 9A). As the 
whole ECM digest was passed through a 100μm strainer, a portion of the DNA, GAG and 
collagen was lost due to the removal of large suspended particulates (Figure 9B). The liquid 







Figure 9. Biochemical characterization of cartilage ECM during preparation. (A) 
Decellularization. (B) Removal of suspended particulates from the liquid fraction of ECM 
obtained by ECM digestion. (n=4, two independent experiments) 
3.4.2 Effects of ECM on MSCs without differentiation stimuli 
The ECM regulates growth and metabolism of stem cells in a tissue-specific manner. 
O’Neill et al. showed that stem cells exhibit decreased proliferation but higher metabolism when 
cultured in their parent ECM (2013). On the contrary, when cultured in ECM not derived from 
their native tissue, stem cells exhibited increased proliferation and lower metabolic activity. We 
asked whether the cartilage ECM has similar effects on MSCs, adult stem cells not derived from 
cartilage. 
The effects of ECM were analyzed in three culture formats: media supplement at a 
concentration of 0.1mg/ml, hydrogel at a concentration of 3mg/ml, and coating. The media 
supplement was prepared by 100 fold dilution from 10mg/ml ECM digest, which was derived 





media with 10% FBS but no other exogenous growth factors and differentiation stimuli. Indeed, 
ECM promoted MSC proliferation and inhibited metabolism in all three formats, consistent with 







Figure 10. Cartilage ECM promoted proliferation and inhibited metabolism in MSCs without 
exogenous differentiation stimuli. ECM was assayed as (A) media supplement, (B) hydrogel, and 
(C) surface coating. ECM hydrogel was prepared as 50% mixture with collagen I due to the 
inability of 100% ECM to gel. (n=4, two independent experiments) 
3.4.3 Chondrogenic effects of ECM on MSC differentiation 
We first studied whether cartilage ECM has effects on chondrogenic differentiation. MSC 
pellets were cultured in the presence or absence of liquid ECM supplementation for up to five 
weeks, and analyzed for chondrogenic gene expression, biochemical contents, and histology 
(Figure 11A). From week 2 to 5, ECM supplementation resulted in greater pellet weight, higher 
DNA, GAG, and collagen content (Figure 11B). This promotive effect on chondrogenesis was 
accompanied by increased expression of chondrogenic and cartilage matrix genes such as Sox 
5/6/9, aggrecan, collagen II, and CSGALNACT1 (Figure 11C). Consistently, histology showed 














Figure 11. Cartilage ECM promoted MSC proliferation and chondrogenesis as media supplement. 
(A) Experimental scheme. (B) Effects on pellet wet weight, DNA, GAG, and OHP contents. 
(n=5) (C) Effects of cartilage gene expression (n=6). (D) Histological sections of pellets; arrows 
show the formation of lacunae (n=4). Scale bar = 100μm. Experiments were replicated with two 
sources of ECM and two sources of MSCs. 
To further confirm the chondrogenic effects of ECM, a gradient dose of ECM was added 
to the MSC chondrogenic culture and analyzed at week 3 (Figure 12A). With increasing doses 
of ECM, pellet diameter, weight, DNA, GAG, and OHP contents were elevated (Figure 12B), 











Figure 12. Dose response of ECM supplementation on MSC chondrogenesis at week 3. (A) 
Experimental scheme. (B) Pellet diameter, weight, and biochemical contents (n=5). (C) 
Histology staining (n=4). Scale bar = 100μm. Results were confirmed in two independent 
experiments. 
 Chondrogenesis can be divided into early, mid, and late stages. We asked whether the 
ECM effects were time-dependent. ECM was supplemented to the MSC culture at early (1st 
week), mid (2nd week), and late (3rd week) stages of chondrogenic differentiation (Figure 13A). 
Supplementation at any of the three stages resulted in an increase in GAG, but not collagen, with 
the strongest effect observed during the first week (Figure 13B). However, supplementation 
during any single week still resulted in less matrix formation and pellet growth than continuous 
supplementation throughout the three weeks. Notably, although supplementation during mid and 
late stages of chondrogenesis alone resulted in minor enhancement in pellet growth, these 
changes greatly augmented the effects of ECM supplementation during early chondrogenesis. 
These results suggest that cartilage ECM had the greatest chondrogenic effects at early stage of 







Figure 13. Differential effects of ECM during different stages of MSC chondrogenesis. (A) 
Experimental scheme. (B) Effects on pellet diameter, wet weight, and biochemical contents (n=5, 
one independent experiment).  
 Since early chondrogenesis was most sensitive to ECM regulation, we asked whether the 
effect of early ECM supplementation produced long-lasting outcomes in cartilage matrix 
production. We compared ECM treatment for the initial 5 days of culture with continuous ECM 
treatment and no-treatment control (Figure 14A). Surprisingly, early treatment for as short as 5 
days resulted in greater DNA, GAG, and collagen contents than control, and the effects were 
intermediate between that of continuous ECM supplementation and control (Figure 14B). This 
long-lasting effect of ECM in early chondrogenesis suggests that cartilage ECM may guide 







Figure 14. Long-lasting chondrogenic effects of ECM supplementation during early 
chondrogenesis. (A) Experimental scheme. (B) Effects on biochemical contents. (n=5, one 
independent experiment). 
3.4.4 ECM promoted a mature, hyaline-like cartilage phenotype 
In vivo, cartilage develops from stem cells differentiating into immature chondrocytes, 
mature chondrocytes, pre-hypertrophic chondrocytes, and finally to late/terminal hypertrophic 
chondrocytes. This increasing degree of differentiation is accompanied by changes in gene 
expression profile and cartilage matrix components as well. As shown above, ECM 
supplementation during early chondrogenesis had long-lasting effects on MSC differentiation. If 
the early ECM treatment increased the degree of differentiation for MSCs relative to control, this 
may, at least in part, explain why the ECM-treated MSCs continued to produce greater cartilage 
matrix without ECM stimulation later on. Since the ECM was derived from the mature tracheal 
cartilage from adult pigs, we asked whether this mature ECM material could increase the 





Indeed, the ECM-treated cartilage showed higher expressions of cartilage maturity 
markers such as collagen X, Mef2c, and Zfp521, indicating a higher maturity of chondrogenic 
differentiation (Figure 15). Collagen X is typically used as a marker for spontaneous 
hypertrophy of MSC cultures in vitro. However, the increased collagen X expression in this 
experiment does not indicate higher tendency of hypertrophy, as will be shown in section 3.4.6. 
 
Figure 15. ECM supplementation increased expression of cartilage maturity markers (n=6). 
Experiments were replicated in two MSC sources and with two ECM sources.  
There are three major subtypes of cartilage: hyaline, fibrous, and elastic. Articular 
hyaline cartilage, when damaged, regenerates into a fibrous repair tissue, which is more prone to 
degeneration and osteoarthritis, and has inferior biomechanical properties than native cartilage, 
partially due to the higher collagen I content, and lower collagen II and GAG contents. Current 
efforts in cartilage tissue engineering has not been successful in generating bona fide hyaline 





ECM was derived from hyaline tracheal cartilage, we asked whether this hyaline ECM could 
steer the MSC differentiation towards a hyaline-like subtype. 
We selected a panel of marker genes that are characteristic of hyaline cartilage versus 
fibrous cartilage, based on literature reports (Mienaltowski et al., 2009, 2010). ECM 
supplementation resulted in higher expression levels of hyaline markers but little change in non-
hyaline markers (Figure 16). These results suggest that treatment by a hyaline cartilage ECM 













Figure 16. ECM supplementation promoted a hyaline-like expression profile in MSCs. (A) 
Hyaline marker genes. (B) Non-hyaline marker genes. (n=6, one independent experiment) 
3.4.5     Chondroprotective effects of ECM under catabolic stimuli 
In degenerative diseases such as OA, cartilage catabolism is induced by pro-
inflammatory cytokines such as IL-1β and reactive oxygen species (ROS), among others. Since 
ECM promoted MSC chondrogenesis and cartilage matrix production, we asked whether ECM 
can be chondroprotective under catabolic stimuli. 
Chondrogenic cultures of MSCs were treated with hydrogen peroxide and IL-1β to 
induce catabolism, and ECM was supplemented throughout the culturing period. At week 2, 
ECM alleviated the catabolic effects on DNA, GAG, and collagen production in MSCs (Figure 
17A, B). This chondroprotective effect was consistent at week 3 in MSCs and in human 
osteoarthritis chondrocytes (Figure 17C, D). These results suggest that a healthy cartilage ECM 








Figure 17. ECM supplementation reduced the catabolic effects of hydrogen peroxide (A) and IL-
1β (B) in MSCs. A time course of 3 weeks was evaluated in MSCs (C) and osteoarthritic 





3.4.6 ECM inhibited hypertrophy and endochondral ossification in MSC-derived 
chondrocytes 
In healthy articular cartilage, the chondrocyte phenotype is maintained without 
hypertrophic changes.  In osteoarthritis and cartilage injury, however, chondrocytes undergo 
hypertrophic degradation and abnormal calcification. The role of cartilage ECM in maintaining 
stable cartilage and preventing progression to hypertrophy has not been studied. We hypothesize 
that healthy hyaline cartilage ECM may contribute to cartilage maintenance and inhibition of 
chondrocyte hypertrophy.  
In vitro, hypertrophic maturation of MSCs progresses through an early chondrogenic 
phase (2-4 weeks) and a later hypertrophic phase (3 weeks). Therefore, ECM was supplemented 
to the chondrogenic phase or hypertrophic phase or both. Samples were analyzed for biochemical 
compositions, calcium deposition, mineral formation, and qPCR gene expression, at early 













Figure 18. ECM supplementation inhibited hypertrophy and endochondral ossification. “+” 
indicates presence of ECM supplementation and “–” indicates no ECM supplementation. (A) 
Experimental scheme. (B) Pellet diameter and biochemical compositions (n=4). (C) Calcium 
quantification and mineral formation assayed by micro-CT (n=6). (D) Histology (n=4). Scale bar 
= 100μm. Experiments were replicated with two ECM sources and two MSC sources.  
 ECM supplementation exhibited timing-dependent effects. Strikingly, ECM 
supplementation during the chondrogenic phase eliminated mineral deposition in the pellet, 
regardless of the presence of ECM supplementation during the hypertrophic phase, whereas 
ECM supplementation during the hypertrophic stage had no significant effects (Figure 18C). 
The inhibitory effect of ECM supplementation during the chondrogenic phase was further 







Figure 19. ECM supplementation during the chondrogenic phase inhibited expression of 
hypertrophic and ossification markers (n=6). Experiments were replicated with two ECM sources 






3.4.7     ECM delayed, but did not prevent endochondral ossification in MSCs 
Since ECM supplementation during the chondrogenic phase inhibited endochondral 
ossification for 3 weeks, we asked whether this inhibitory effect was temporary or permanent. To 
address this question, MSC pellets were cultured in hypertrophic medium for up to 5 weeks, and 
the inhibitory effect on endochondral ossification was no longer present (Figure 20). 
Interestingly, the level of calcium deposition was similar whether the pellets were treated with 
ECM or not, indicating that ECM supplementation only temporarily delayed endochondral 
ossification rather than preventing it permanently. 
 
Figure 20. ECM supplementation during chondrogenic phase delayed, but did not prevent 
mineralization of MSC pellets. MSCs were cultured chondrogenically for 4 weeks before 3-5 







3.4.8 Identifying strategies to improve cartilage maintenance at terminal hypertrophy 
 In cartilage injury repair and degenerative diseases, the goal is to create stable cartilage 
without progression to hypertrophy and endochondral ossification. Since ECM supplementation 
during the chondrogenic phase inhibited cartilage matrix accumulation at terminal hypertrophy, 
we sought to find strategies to improve the maintenance of cartilage matrix. We hypothesize that 
greater amount of cartilage matrix production before the initiation of hypertrophic culture would 
result in better cartilage preservation, and studied if this may be achieved by higher dosing and 
long culture duration of ECM supplementation during the chondrogenic phase. 
 In the first strategy, MSCs were cultured with a gradient dose of ECM supplementation 
during the chondrogenic phase (Figure 21). This resulted in a higher level of matrix production 
at the end of chondrogenic phase and a higher level of GAG at terminal hypertrophy at the 
highest ECM dose. Notably, a lower ECM dose at 0.05mg/ml, failed to inhibit calcium 






Figure 21. Dose response of ECM supplementation on cartilage preservation at terminal 
hypertrophy (n=6, one independent experiment). 
 In the second strategy, MSCs were cultured chondrogenically for longer duration (2-4 
weeks) before hypertrophic differentiation. Longer chondrogenic culture resulted in higher 
cartilage matrix production before hypertrophic differentiation and at terminal hypertrophy 
(Figure 22). These two strategies serve as first steps towards promoting chondrogenesis while 
limiting hypertrophy during cartilage repair and regeneration. 
 
Figure 22. Longer chondrogenic culture increased preservation of cartilage matrix at terminal 
hypertrophy (n=6, one independent experiment). 
3.5 Discussion 
Normal cartilage consists of ECM and chondrocytes that stay in homeostasis. Healthy 
chondrocytes should be differentiated enough to provide a stable supply of matrix materials, but 





between under-differentiation and over-differentiation, with under-differentiation causing weak 
biomechanical properties, and over-differentiation causing cartilage degradation and hypertrophy 
as seen in osteoarthritis. In this work, we show that healthy hyaline cartilage ECM promotes 
chondrogenesis of MSCs and the maturity of the resulting chondrocytes, but inhibits 
hypertrophic differentiation and endochondral ossification. Therefore, a healthy ECM may help 
resident cells to maintain the fine balance of differentiation. It remains of interest to study 
whether a diseased cartilage ECM, such as from OA, has lost the function of maintaining the 
proper degree of differentiation for chondrocytes or even drives chondrocytes to over-
differentiation and hypertrophy. 
In cartilage injury, the remaining ECM and chondrocytes, for the most part, do not 
migrate to the defect on their own, and the defect remains unhealed. Even following 
microfracture, the MSCs released from subchondral bone rebuild a layer of fibrocartilage, which 
is usually thinner and weaker than the native tissue. The lack of ECM at the defect may be a 
contributing factor to the inability of healing. Since a healthy ECM promotes chondrogenesis, 
cartilage matrix production, and a hyaline phenotype, it begs the question of whether adding 
healthy ECM to the cartilage defect after microfracture can direct the MSCs to form neocartilage 
that more closely resembles the native hyaline cartilage, biochemically, structurally, and 
mechanically. This approach may improve the outcome of existing microfracture surgeries for 
full-thickness cartilage injury.  
In degenerative diseases such as OA, chondrocytes exhibit hypertrophic changes and lose 
their ability to form healthy matrix; the diseased ECM may further feed back to the resident 
chondrocytes to drive their over-differentiation and hypertrophy. In this study, we showed that 





IL-1β. This result inspires a therapeutic approach of intercepting the potential downward spiral 
of diseased ECM and diseased chondrocytes by providing healthy ECM to the diseased sites to 
restore proper functioning of chondrocytes. 
 Intriguingly, the hyaline ECM directs MSCs to a hyaline phenotype, with increased 
expression of collagen II and GAGs and unchanged expression of collagen I. In the development 
of cellular therapies for cartilage repair, it remains a long-standing challenge to avoid 
fibrocartilage and create true hyaline cartilage. Whether the compositions and mechanics of our 
ECM-treated cartilage match true hyaline cartilage is yet to be tested, but it serves as a major 
















Chapter 4. Identifying signaling pathways and bio-active components in ECM that regulate 
MSC chondrogenesis 
4.1 Abstract 
The PI3K-Akt-Foxo1 and Hif1 pathways were identified as possible mediators of ECM 
regulation of MSC chondrogenesis, Collagen XI was identified as a chondrogenic component of 
the ECM. Collagen XI promoted cartilage matrix formation in MSC and chondrocyte pellets, and 
inhibited matrix degradation in human chondrocytes and bovine cartilage explants. 
4.2 Background  
The cartilage ECM is a heterogeneous material, in which different components may exert 
their own effects on MSCs or chondrocytes, with complex synergies or counteractions with one 
another. Chondrogenic differentiation is regulated by a network of signaling pathways including 
Hif1/2 and PI3K-Akt-Foxo (Lee et al., 2013) that regulate cell proliferation, degree of 
differentiation, and matrix production.  
To study the mechanisms of ECM regulation of MSC chondrogenesis, we employed two 
approaches. In the first approach, RNA seq analysis was conducted to compare the differential 
expression and signaling pathways between ECM-treated and control MSCs. These pathways 
were then confirmed with inhibitor assays for these pathways. In the second approach, we 
attempted to identify individual bioactive components from the ECM digest. Selective enzymes 
were used to degrade specific components from the ECM and the bioactivity of the resulting 








4.3.1 RNA seq analysis 
RNAs were sequenced and analyzed by Admera Health (South Plainfield, NJ). The 
differentially expressed genes were benchmarked against the KEGG database to obtain signaling 
pathways with differential activity. ECM was supplemented at 0.2mg/ml in the MSC cultures for 
RNA isolation. 
4.3.2 Enzymatic digestion of decellularized cartilage ECM  
ECM was digested with pepsin (1mg/ml) overnight, collagenase I (1U/ml) for 2 hours, 
chondoitinase ABC (0.2mg/ml) overnight, and hyaluronidase (0.2mg/ml) overnight. The 
enzyme-digested ECM was added to the MSC chondrogenic culture for 2 weeks, and analyzed 
for biochemical contents. As positive and negative controls, respective enzymes were added 
directly to MSC cultures with and without ECM supplementation (0.2mg/ml). 
4.3.3 Cartilage pellet degradation assay 
Chondrocytes pellets were formed by centrifuging 200,000 cells at 300g for 5 minutes. 
The pellets were cultured in chondrogenic media for 6 days and switched to 1ml DMEM with 
50μg/ml ascorbic acid for 3 days. Interleukin-1β (1ng/ml) was supplemented to some pellets to 
enhance degradation (Peprotech, Rocky Hill, NJ). Conditioned medium was collected and 
assayed for DNA and GAG concentrations. 
4.3.4 Culture of bovine cartilage explants 
Fresh calf wrists were obtained from Green Village Packing (Green Village, NJ) and 





into 1mm disks. The cartilage disks were stabilized in DMEM with 10% fetal bovine serum and 
50μg/ml ascorbic acid for at least six hours, and switched to 1ml of DMEM with 50μg/ml 
ascorbic acid for 3 days. 
4.3.5 Statistical analysis 
Statistical analysis was performed with GraphPad Prism 6.0. Data were expressed as the 
average +/- standard deviation. The differences in gene expression and biochemical contents 
between the groups were evaluated using two-way ANOVA with Bonferroni post hoc test, with a 
significant level at 0.05. 
4.4 Results 
4.4.1     Differentially regulated signaling pathways by ECM 
RNA seq analysis revealed 1198 differentially expressed genes, from which 17 
differentially activated and 10 differentially inhibited pathways by ECM supplementation were 
inferred (Table 1). Hif1 and PI3K-Akt pathways were differentially activated whereas Foxo 
pathway was differentially inhibited. Interestingly, these three pathways were implicated in Lee 
et al., who showed that hypoxia enhanced chondrogenesis and prevented terminal differentiation 
through PI3K-Akt/Foxo dependent anti-apoptotic effects (Lee et al., 2013). In their study, MSC 
pellets cultured in hypoxia showed increased p-Akt and p-Foxo levels. Since cells respond to 
hypoxia by activating Hif1/2 pathways, it is conceivable that, under hypoxia, MSCs may 
upregulate an integrated Hif-PI3K-Akt-Foxo pathway to promote chondrogenesis and inhibit 






                 
Table 1. List of differentially activated (left) and inhibited (right) pathways by ECM 
supplementation. Three pathways marked in red were subject to further study. The p values 
corresponded to the statistical significance of each activated and inhibited pathways. (n=4 for 
RNA seq analysis) 
4.4.2 Inhibitors of PI3K-Akt-Foxo1 pathway eliminated the chondrogenic effects of ECM 
To confirm the role of the PI3K-Akt-Foxo1 pathway, MK2206 (inhibitor of PI3K 
activity), LY294002 (inhibitor of PI3K activity), wortmannin (inhibitor of PI3K activity and 
Foxo nuclear export), and leptomycin B (inhibitor of Foxo nuclear export) were added to the 
MSC cultures with and without ECM supplementation. If the inhibitor was able to reduce or 
eliminate the difference in matrix production and gene expression caused by ECM 
supplementation, the inhibited pathway should be a mediator of the ECM effect. Indeed, all four 
inhibitors eliminated the increased GAG production, Sox9 expression, Acan expression, and 
Col2A1 expression caused by ECM supplementation, which confirms that PI3K-Akt and Foxo1 












Figure 23. Inhibitors of the PI3K-Akt and Foxo pathways eliminated the differential effects 
caused by ECM supplementation. (A) MK2206. (B) LY294002. (C) wortmannin. (D) 





4.4.3 Inhibitors of Hif1 eliminated the chondrogenic effects of ECM 
Similar inhibitor assays were conducted for the Hif pathway. PX-478, a specific Hif1α 
inhibitor, was able to eliminate the chondrogenic effects caused by ECM, as indicated in GAG 
quantification and expression of Sox9, Col2A1, and Acan (Figure 24). In comparison, TC-S 
7009, a specific Hif2 inhibitor, had no effect on MSC chondrogenesis in the presence or absence 
of ECM supplementation.  
 
Figure 24. Hif1, but not Hif2, inhibition eliminated the effects of ECM. (n=4, one independent 
experiment)  
4.4.4 Selective enzymatic digestions of ECM 
The cartilage ECM consists of collagen, GAG, hyaluronic acid, and other proteins. To 
identify whether these components contribute to the chondrogenic effects of ECM, pepsin, 





the ECM, and the chondrogenic activity of the resulting enzyme-degraded ECM was quantified 
by their effects of cartilage matrix production in MSC cultures. 
 Pepsin treatment eliminated the effect of ECM on GAG production, but only partially 
eliminated the effect of ECM on collagen production (Figure 25A). This suggests that the 
protein components of ECM contributed to the majority, but not all, of its chondrogenic effects. 
Collagenase treatment partially eliminated the effect of ECM on GAG production, but fully 
eliminated the effect on collagen production (Figure 25B), suggesting that collagenous 
components of the ECM also contributed to this chondrogenic effects. Chondroitinase treatment 
did not affect GAG or collagen production, suggesting an insignificant role for GAG in 
promoting chondrogenesis (Figure 25C). Lastly, hyaluronidase treatment partially reduced the 
effects of ECM on GAG and collagen production (Figure 25D), indicating a chondrogenic role 









Figure 25. Enzyme-treated ECM preserved different levels of chondrogenic activities in MSC 
culture. (A) Pepsin. (B) Collagenase. (C) Chondroitinase ABC. (D) Hyaluronidase. (n=4) 






4.4.5 Screening of collagen subtypes for chondrogenic activity 
 Since collagenous components of the ECM contributed to its chondrogenic effects, a 
screen of various collagen subtypes were conducted on MSCs. Native soluble collagens from 
human or pig, in all commercially available subtypes (I, II, III, IV, V, VI, IX, XI) were added to 
MSC chondrogenic cultures and analyzed for their effects on DNA, GAG, and collagen 
production at week 2. Strikingly, collagen XI exhibited a dose-dependent positive effect on GAG 
and collagen production (Figure 26). At 100μg/ml collagen XI, the effect was comparable to 
ECM supplementation at 0.2mg/ml. In addition, collagen I seemed to have a positive effect on 
collagen production, but this was likely due to visible precipitation of streaks of collagen I fibrils 
attached to the MSC pellets instead of from endogenous production by MSCs. Interestingly, 
collagen II seemed to have a slight inhibitory effect on GAG production, although these results 
need to be reproduced. (Porcine collagen I: Chondrex 1203; Porcine collagen II: Chondrex 
20032; Human collagen III: Abcam 7535; Human collagen IV: Abcam 7536; Human collagen V: 
Abcam 7537; Human collagen VI: Abcam 7538; Porcine collagen IX: Chondrex 1073; Porcine 







Figure 26. Effects of collagen subtypes on MSC chondrogenesis (n=4, one independent 
experiment). 
Since collagen XI was found to promote MSC chondrogenesis, its biological effects was 
further studied. Native porcine collagen XI was digested by pepsin (2ng per μg of collagen at 
37oC for 30 minutes) to cleave off the N-terminal telopeptide and preserve the triple-helical 
regions only (Vogel et al., 1997). Native porcine collagen XI was also permanently heat-
denatured at 45oC for 30 minutes to dissociate the triple helix to three individual α chains (Vogel 





chondrogenic activities. Removal of the N-terminal telopeptide and dissociation of the α chains 
destroyed the activity. 
Figure 27. Chondrogenic activities of collagen XI in MSCs. (A) Comparing native, pepsin-
degraded, and heat-denatured collagen XI (n=4, two independent experiments). 
4.4.6 Collagen XI promoted matrix production in human chondrocytes 
Since collagen XI promoted cartilage matrix formation in MSCs, we asked whether this 
effect was reproducible in chondrocytes. From week 2-3, collagen XI supplemented to the media 
resulted in greater DNA, GAG, and OHP contents in the pellets, which was accompanied by 
elevated expression of Col2A1, Sox9, and Acan (Figure 28). Note that Col2A1 expression was 












Figure 28. Collagen XI promoted cartilage matrix formation in human chondrocytes. Healthy 
human chondrocytes were cultured chondrogenically for 2-3 weeks with collagen XI 
supplementation in the media. Biochemistry and gene expression (at week 2) of the pellets were 
analyzed. Experiments were replicated with two sources of MSCs (n=5).  
4.4.7 Collagen XI inhibited matrix degradation 
We further asked whether collagen XI has any effects on degradation of cartilage matrix. 
In human chondrocyte pellets, collagen XI supplementation resulted in decreased DNA and 
GAG contents released to the conditioned media, indicating less cell death and matrix 
degradation (Figure 29A). Similarly, GAG degradation was inhibited by collagen XI in bovine 






Figure 29. Collagen XI inhibited degradation of cartilage matrix in human chondrocyte pellets 
(A) and bovine articular explants (B). Experiments were replicated in greater than three sources 
of bovine explants (n=6). 
 4.5        Discussion 
This section aims to identify the mechanisms that mediate ECM regulation of 
chondrogenesis. Selective enzyme degradation of ECM components reveals a potential role of 
hyaluronic acid (HA) in promoting chondrogenesis. Indeed, after intra-articular injections of HA 
in OA patients, exogenous HA, in addition to its visco-lubricative function, is incorporated into 
articular cartilage where it may have a direct biological effect on chondrocytes through CD44 
receptors (Akmal et al., 2005). In vitro, low concentrations of HA (0.1mg/ml and 1mg/ml) 





et al., 2005). In rat articular chondrocytes, HA inhibits IL-1β-induced chondrocyte apoptosis in a 
dose-dependent manner, by inhibiting inducible oxide synthase (responsible for NO production), 
reducing the impairment of the mitochondrial membrane potential, and restoring mitrochondrial 
ATP production (Zhou et al., 2008). The anabolic effect of HA can be further augmented by 
hypoxia (Ichimaru et al., 2016). Our discovery of a contribution of HA to the chondrogenic 
effects of cartilage ECM is consistent with these prior studies. Since HA is used for pain relief in 
OA, it may also be useful as a scaffold for cartilage tissue engineering. 
The identification of collagen XI as a critical chondrogenic component in the ECM 
preparation serves as a first step towards uncovering the specific matrix molecules in regulating 
resident cells of the cartilage. In articular cartilage, collagen XI is present within the collagen II-
XI-IX bundles (Blaschke et al., 2000). The N-terminal telopeptide of collagen XI is present on 
the surface of the bundle, while the triple-helical tail is intermingled with the collagen II and IX 
fibrils (Blaschke et al., 2000). Physiologically, collagen II binds to discoidin domain receptor 2 
(DDR2) on chondrocytes to regulate matrix production, degradation, hypertrophic differentiation, 
and inflammatory cytokine production (Klatt et al., 2009). The unique structure of the collagen 
II-XI-IX bundle may suggest a role of collagen XI in blocking the interactions between collagen 
II and DDR2 by covering the surface of the collagen bundles. Indeed, in mouse, collagen XI 
haplo-insufficiency results in early onset of osteoarthritis, which can be rescued with DDR2 
haplo-insufficiency (Salazar et al., 2014; Xu et al., 2003). In our study, collagen XI promoted 
cartilage matrix production and strongly upregulated the expression of collagen II relative to the 
expression of Sox9 and Acan. Our results support the hypothesis that collagen XI, by blocking 
the interaction between collagen II and DDR2, prevents chondrocytes from “seeing” collagen II 





We found that not only collagen XI promoted matrix anabolism, but it also inhibited 
matrix catabolism. In the human chondrocyte pellets, collagen XI reduced the release of DNA 
and GAG, indicating less cell death and matrix degradation. In mice, collagen XI deficiency 
causes increased expression of DDR2 and MMP13 in temporomandibular joint cartilage, 
promoting cartilage degradation (Lam et al., 2007). In human articular cartilage, some 
polymorphisms in collagen XI are associated with greater propensity for osteoarthritis 
(Rodriguez-Fontenla et al., 2014; Jakkula et al., 2005). For human lumbar disc cartilage, a 
collagen XI polymorphism that results in decreased mRNA stability has been associated with 
disc herniation (Mio et al., 2007). Taken together, these results support the protective role of 
collagen XI in maintaining healthy cartilage. 
The potential involvement of PI3K-Akt-Foxo1 and Hif1 in promoting chondrogenesis is 
consistent with findings by Lee et al. (2013). In their paper, hypoxia enhances chondrogenesis 
and prevents terminal differentiation through PI3K-Akt-Foxo dependent pathways in MSCs. In 
our study, cartilage ECM also promotes MSC chondrogenesis via PI3K-Akt-Foxo pathway. In 
chapter 3, we demonstrated that ECM inhibits hypertrophy and endochondral ossification in 
MSCs, which is consistent with Lee’s findings. Therefore, we propose that cartilage ECM, 
similar to hypoxia, promotes MSC chondrogenesis and inhibits hypertrophic differentiation via a 
common PI3K-Akt-Foxo and Hif1 pathway. 
Although multiple signaling pathways and ECM components with potential chondrogenic 
activities were identified in this study, they do not encompass the totality of the multiplex effects 
of cartilage ECM. Further studies are required to unravel novel signaling pathways and ECM 






Chapter 5. Pharmacological activation of the Hif pathway promotes chondrogenesis and 
inhibits cartilage degradation 
5.1 Abstract 
Roxadustat, a small molecular weight stabilizer of Hif, promoted cell proliferation, 
chondrogenesis, cartilage matrix production, and a hyaline phenotype, and inhibited hypertrophy 
and matrix degradation. These effects were reproducible in MSCs, healthy and OA chondrocytes 
in the presence and absence of IL-1β stimulation. In a bovine articular cartilage explant model, 
roxadustat inhibited GAG degradation. Overall, pharmacological activation of the Hif pathway 
promotes chondrogenesis and inhibits cartilage degradation.  
5.2 Background 
Cartilage injury does not heal without interventions. For superficial injuries of the 
articular surface, the surface is typically debrided to remove any fibrillated tissues that may 
cause mechanical resistance and inflammation (Peretti et al., 2011). However, the remaining 
cartilage does not regenerate to fill the defect, and tends to degenerate into osteoarthritis. For 
full-thickness lesions that reach the calcified cartilage or subchondral bone, a common procedure 
is microfracture, during which the subchondral bone is drilled to release blood and bone marrow 
MSCs into the joint space, which causes a typical healing response. However, the regenerated 
cartilage is fibrous subtype that is thinner, mechanically weaker, and poorer in collagen II and 
GAG. These fibrocartilage, too, is prone to hypertrophy and degeneration into OA. Therefore, 
the goal of treating cartilage injury is to restore the hyaline cartilage with similar biochemical 






Osteoarthritis is a progressive degenerative disease of the joint that causes pain, 
dysfunction, and disabilities. It is characterized by gradual loss of articular cartilage, sclerosis of 
subchondral bone, formation of osteophyte, and chronic low grade inflammation (Ashkavand et 
al., 2013). Early and mid-stage OA is managed by pain and anti-inflammatory medications and 
intra-articular injection of a viscosupplement hyaluronic acid. Late-stage OA can only be treated 
with joint replacement surgery. However, there is no disease-modifying therapy for OA, which 
can slow down or reverse the loss of cartilage. 
 In OA, aging, cumulative mechanical injuries, and other unknown causes initiate the 
downward spiral of the disease (Ashkavand et al., 2013). Cartilage ECM is gradually lost from 
the articular surface, which weakens the cartilage and causes inflammation due to fibrillation. 
Pro-inflammatory cytokines such as IL-1β and TNF-α cause activation of chondrocytes and 
synoviocytes, which further exacerbates chronic inflammation. Chondrocytes and synoviocytes 
also upregulate degradative enzymes such as MMP13 and ADAMTS5, which further break 
down ECM materials including GAG and collagens. The fragmented ECM lingers in the joint 
space and exacerbates inflammation and matrix degradation. Chondrocyte death is also observed. 
At the same time, the biomechanics of the joint is altered and subchondral bone weakens due to 
the formation of bone cysts and sclerosis, characterized by increased bone turnover, high 
collagen content, but under-mineralization. In this way, the cartilage loss and bone disease 
interact to drive OA progression. 
For both cartilage injury and OA, a desired treatment should demonstrate the following 
properties: 
i. Promoting cell survival and proliferation 





iii. Inhibiting matrix degradation 
iv. Promoting a hyaline phenotype  
v. Inhibiting hypertrophy 
To this goal, we asked whether roxadustat, a Hif stabilizer that inhibits prolyl 
hydroxylase domain 2 (PHD2) and raises levels of Hif1α, can recapitulate the signaling effects of 
ECM. We determined its effects on chondrogenesis and matrix degradation in MSCs, healthy 
human chondrocytes, OA chondrocytes, and bovine cartilage explants.  
5.3 Methodology 
5.3.1     qPCR analysis of cartilage explants 
To harvest mRNA from cartilage explants, the cartilage discs from the same calf was 
collected and immersed in 1ml Trizol regent. The cartilage discs were frozen and thawed once, 
and the Trizol was used for further mRNA isolation, and qPCR analysis. 
5.3.2 Western blotting 
Cell pellets or monolayers were lysed in 2x Laemlli dye and run on a polyacrylamide gel 
(Biorad, 4561094, Hercules, CA). The proteins were transferred to a nitrocellulose membrane 
and probed with β-actin antibody (1:200, Santa Cruz, 47778, Dallas, TX), Hif1α (1:1000, Cell 
Signaling, 14179s, Danvers, MA), and Hif2α (1:1000, Cell Signaling, 7096). Blots were imaged 








5.3.3     Statistical analysis 
Statistics were performed with GraphPad Prism 6.0 software. Data were expressed as the 
average +/- standard deviation of n=4-6 samples per group. The differences between groups were 
examined by ANOVA (one-way ANOVA with Tukey’s post hoc test or two-way ANOVA with 
Bonferroni post hoc test) with the significance level at 0.05.  
5.4 Results 
5.4.1 Roxadustat stabilized Hif1 and promoted MSC chondrogenesis 
Roxadustat stabilized Hif1α (Figure 30A), and promoted cell proliferation, chondrogenic 
gene expression such as Sox9, Acan, and Col2A1, and GAG/OHP accumulation (Figure 30B, 
C). Hydroxylated collagen was not different from control at week 2, probably due to the non-
specific inhibitory effect of roxadustat on collagen prolyl hydroxylase. Indeed, at roxadustat 
concentration of 10μg/ml, the MSC pellets were very loose and not compact, probably due to the 
lack of hydroxylated collagen in the matrix. Furthermore, these effects of roxadustat were not 
due to Hif2α, since the addition of a Hif2 inhibitor, TC-S 7009, did not affect MSC 

















Figure 30. Signaling and chondrogenic effects of roxadustat in MSCs. (A) Western blots. (B) 
Effects on chondrogenic gene expression and matrix production. (C) Dose response of roxadustat 
on cartilage matrix production at week 2. (D) Effects of Hif2 inhibitor TC-S 7009 on roxadustat 
treatment. (E) Histology at week 2 (n=4 for biochemical quantification and n=6 for PCR, two 





5.4.2     Roxadustat promoted a hyaline-like phenotype and the maturity of chondrogenic 
differentiation 
Similar to ECM supplementation, roxadustat selectively promoted the expression of 
hyaline marker genes and the expression of non-hyaline marker genes were unchanged by 
roxadustat (Figure 31A). Markers of cartilage maturity was also higher with roxadustat 
treatment (Figure 31B). This effect was independent of Hif2 activity. 
 
 
Figure 31. Effects of roxadustat on MSC-derived cartilage. (A) Effects on hyaline vs non-hyaline 






5.4.3 Roxadustat inhibited MMP expression in MSCs 
Roxadustat inhibited expression of MMP13 in MSC chondrogenic culture, independent 
of Hif2 activity (Figure 32A). Under catabolic stimulation of IL-1β, roxadustat also inhibited 









Figure 32. Effects of roxadustat on cartilage matrix degradation genes. (A) Without IL-1β. (B) 
Under IL-1β stimulation. (n=6, one independent experiment) 
5.4.4     Effects of roxadustat on human healthy chondrocytes 
Since roxadustat promoted chondrogenesis and a hyaline phenotype in MSCs, we asked 
whether the same effects could be observed with healthy chondrocytes. Indeed, chondrogenic 
genes including Sox9, Acan, and Col2A1 were upregulated, and higher DNA and GAG 
accumulation were observed (Figure 33A, B). Hydroxylated collagen was decreased with 
roxadustat treatment, likely due to its inhibitory effect on collagen prolyl hydroxylase. The 
chondro-promotive effects on gene expression were also detected in the presence of low dose IL-
1β, which mimicked an OA environment (Figure 33C). Similarly, roxadustat selectively 
enhanced the expression of hyaline marker genes and inhibited the expression of MMP 1/3/13, 













Figure 33. Effects of roxadustat on healthy human chondrocytes. (A) Biochemical quantification. 
(B) Chondrogenic gene expression. (C) Chondrogenic gene expression in the presence of IL-1β. 
(D) Effects on hyaline vs non-hyaline marker genes. (E) Effects on degradative gene expression. 
(n=4-6, one independent experiment) 
Roxadustat also inhibited hypertrophy in healthy chondrocyte, demonstrated by the 
inhibition of collagen X, MMP13, and Runx2 expressions (Figure 34A). Importantly, it also 
promoted the preservation of cartilage matrix. The GAG and hydroxylated collagen levels were 
higher when roxadustat was supplemented during the hypertrophic culture with corresponding 
increase in expression of Sox9 and Col2A1 (Figure 34B,C). These results suggest that 







Figure 34. Effects of roxadustat on healthy human chondrocytes during hypertrophy. (A) 
Expression of hypertrophic genes. (B) Biochemical quantification of chondrocyte pellets with 
hypertrophic induction. (C) Expression of chondrogenic genes under hypertrophic induction. 
(n=6, one independent experiment) 
5.4.5 Reproducible effects of roxadustat in human OA chondrocytes 
Consistent with effects on MSCs and heathy chondrocytes, roxadustat promoted the 
proliferation of OA chondrocytes and GAG accumulation, with hydroxylated collagen 
production inhibited, in a dose-dependent manner (Figure 35A). Chondrogenic genes were 
upregulated by roxadustat (Figure 35B). In histology staining of collagen II and collagen I, 
positive staining (indicated by red arrows) was visible in the cartilage lacunae in the roxadustat 
group but not in the control group (Figure 35C). These intracellular collagen deposits were 
likely un-hydroxylated collagen II/I that were unable to be secreted to form the ECM. 






















Figure 35. Effects of roxadustat on chondrogenesis of OA chondrocytes. (A) Biochemical 





Biochemistry and (E) chondrogenic gene expression under IL-1β treatment (n=4-6, one 
independent experiment). Scale bar = 100μm. 
Similar to the effects on MSCs, roxadustat selectively upregulated hyaline marker genes 
and left non-hyaline marker genes unchanged (Figure 36A). Again, MMP13 expression was 
downregulated by roxadustat (Figure 36B). 
 
 
Figure 36. Effects of roxadustat on cartilage matrix and degradation. (A) Hyaline vs non-hyaline 
marker genes. (B) Degradation genes. (n=6, one independent experiment) 
Since cartilage ECM inhibited hypertrophic differentiation in MSC and healthy 





two weeks of chondrogenesis and two weeks of hypertrophic induction, OA chondrocyte pellets 
did not mineralize. However, cell survival and GAG preservation were greater when cells were 
treated with roxadustat during the hypertrophic stage (Figure 37A). Consistently, roxadustat 
enhanced the expression of Sox9, Acan, and Col2A1 when added in the hypertrophic stage 
(Figure 37B). Additionally, treatment by roxadustat during the chondrogenic phase also resulted 
in higher expression of Col2A1 and a positive trend for Sox9 and Acan, indicating that 
roxadustat treatment during the chondrogenic phase could stimulate cartilage matrix production 
under hypertrophy even without roxadustat (Figure 37B). As for hypertrophic markers, collagen 
X and MMP13 were both downregulated by roxadustat at the end of chondrogenic culture, and 
this inhibitory effect carried over to the hypertrophic stage even without roxadustat (Figure 37C). 
Roxadustat did not seem to inhibit hypertrophy as a medium supplement during the hypertrophic 









Figure 37. Effects of roxadustat on hypertrophy in OA chondrocytes. (A) Biochemical 
compositions. (B) Chondrogenic gene expression. (C) Hypertrophic gene expression. “+” 
indicates treatment by roxadustat, and “-” indicates no roxadustat. (n=6, one independent 
experiment) 
5.4.6      Roxadustat inhibited matrix degradation 
With the pro-growth, chondrogenic, anti-catabolic, and anti-hypertrophic effects in cell 
cultures, roxadustat was then studied in bovine cartilage explants ex vivo. Consistently, 
roxadustat promoted chondrogenic gene expressions with and without low and high doses of IL-







Figure 38. Effects of roxadustat on cartilage explants. Chondrogenic gene expression at low dose 
(A) and high dose (B) of IL-1β. (C) Hyaline vs. non-hyaline markers. (n=6, one independent 
experiment) 
Since roxadustat inhibited MMP expression in MSCs and chondrocytes, we asked 
whether it had the same inhibitory effects on MMP1/3/13 expressions. Indeed, at high IL-1β 
concentrations, MMP1 and MMP13 expressions were inhibited (Figure 39A). Furthermore, at 





by roxadustat, regardless of timing of harvest or presence of fetal bovine serum (Figure 39B,C). 
These results suggest that the reduced MMP expression achieved by roxadustat was functional 








Figure 39. Effects of roxadustat on degradation of cartilage explants. (A) Expression of MMPs. 
(B, C) Degraded GAG release to the conditioned medium at different IL-1β doses and serum 
conditions. Experiments were replicated in greater than three sources of bovine explants (n=4). 
5.4.7    Timing effects of roxadustat on osteoarthritic chondrocytes 
Roxadustat promoted chondrogenesis, but its non-specific inhibition of collagen prolyl 
hydroxylase prevented the accumulation of functionally mature collagen II in the ECM, despite 
an upregulation of the Col2A1 gene. How can we promote chondrogenesis with roxadustat 
without the limitation of non-specific inhibition of collagen prolyl hydroxylase? Since ECM 
supplementation during early chondrogenesis produced long-lasting effects, we hypothesized 
that an early treatment by roxadustat might be able to promote cartilage matrix production even 
after being washed out. 
One week of roxadustat treatment resulted in a higher level of GAG at week 2 and 3 than 
control (Figure 40A). Interestingly, the GAG level was similar between continuous roxadustat 
treatment and only one week of treatment. Importantly, one-week treatment of roxadustat 
inhibited hydroxylated collagen production at week 1, but the level caught up with control at 
week 2 and 3, much higher than continuous roxadustat treatment (Figure 40A). These results 
suggest that, similar to ECM, roxadustat also had long-lasting chondrogenic effects, even after 
the drug was absent in the media. 
The long-lasting effects of roxadustat beg the question of how long the effects come into 
being upon drug exposure and how long the effects may last after drug removal. To address the 
former question, OA chondrocyte pellets were cultured in plain chondrogenic media for 3 days 





exposure and subject to qPCR analysis of Sox9, Acan, Col2A1, and MMP13 genes. All genes 
responded within 24 hours, but the onsets of responses were clearly separated into three groups 
(Figure 40B). MMP13 downregulation occurred in the first hour;  Sox9 elevation occurred 
within 4 hours; Acan and Col2A1 responded at 8-24 hours after drug exposure. This differential 
onset of action is consistent with the mechanisms that roxadustat-stabilized Hif1 regulates 
MMP13 and Sox9/Acan/Col2A1 in two distinct pathways. Hif1α is known to inhibit canonical 
Wnt, thus inhibiting MMP13 (Bouaziz et al., 2015). Hif1α is also known to directly activate 
Sox9 expression, which further drives Acan and Col2A1 expression. In this experiment, these 
two distinct downstream signaling effects were confirmed in OA chondrocytes. 
To study the long-lasting effects of roxadustat, OA chondrocytes were cultured in the 
presence or absence of roxadustat for 6 days to achieve a baseline, and then washed out without 
the drug. Sox9, Col2A1, and Acan expression returned to baseline within 24 hours, but MMP13 
expression returned to baseline between 1 and 3 days (Figure 40C). Consistent their differential 
onset of action, the differential duration of washout suggest two distinct signaling pathways 
between MMP13 and Sox9/Acan/Col2A1. Interestingly, MMP13 was the first to respond to 











Figure 40. Timing effects of roxadustat in OA chondrocytes. (A) Long-lasting effect from first 
week of roxadustat treatment. (B) Onset of action of different responsive genes. (C) Duration of 
drug washout. (n=6, one independent experiment) 
5.5        Discussion 
In MSCs, roxadustat promoted cell proliferation, chondrogenesis, cartilage matrix 
production, and a hyaline phenotype, and inhibited MMP1/3/13, independent of Hif2. In addition 
to the above effects, roxadustat also inhibited hypertrophy in healthy and OA chondrocytes. 
These effects were also translatable to bovine articular cartilage explants, and resulted in a 
decrease in GAG degradation, in the presence and absence of serum. These diverse and 
consistent effects of roxadustat are highly desirable for treating cartilage injury and OA. 
How does roxadustat-induced Hif1 stabilization achieve these downstream effects? 
Hypoxia activates PI3K-Akt, which is a known signal for cell growth and proliferation (Lee et al., 
2013). In MSC chondrogenesis, PI3K-Akt inhibits apoptosis and hypertrophic markers such as 
Runx2 and Col10A1, and promotes chondrogenic markers such as Sox9, Acan, and Col2A1 (Lee 
et al., 2013) (Figure 41). Hif1α also directly binds the promoter of Sox9 and promote its 
expression, which further acts as a transcription factor for Acan and Col2A1 (Duval et al., 2009). 
Hif1α also inhibits the Wnt/β-catenin pathway and downregulates MMP13 (Bouaziz et al., 2015) 
and MMP1/3 (Deshmukj et al., 2016). The mechanisms of Hif1 activation of hyaline cartilage 
markers selectively is unknown.  
Overall, these studies provide the evidence that small molecule activation of Hif1 
promotes chondrogenesis and inhibits hypertrophy and degradation. Equally importantly, a 





beneficial effects on cartilage invite therapeutic development of this class of Hif1 stabilizers in 
cartilage injury and OA. In addition to the effects on cartilage, the role of Hif1 on other joint 
structures such as the subchondral bone, synovium, meniscus, and the ligaments should also be 
elucidated for successful therapeutic development. 
 
Figure 41. Proposed signaling mechanism for the effects of roxadustat on cartilage. PHD: prolyl 












Chapter 6. Summary and future directions 
 This thesis focuses on the regulatory role of cartilage ECM to promote chondrogenesis 
and inhibit hypertrophy. By recapitulating the signaling pathways and providing chondrogenic 
components of the ECM, similar effects can be obtained by therapeutic molecules in the absence 
of ECM.  
Indeed, we showed that cartilage ECM promoted chondrogenesis and cartilage matrix 
production in MSCs. It increased the maturity of MSC differentiation and steered it towards a 
hyaline-like phenotype. The chondrogenic effects were strongest during early differentiation, and 
were long-lasting till at least 5 weeks. ECM was also chondroprotective when MSCs and OA 
chondrocytes were treated with a catabolic IL-1β stimulus.  
Cartilage ECM inhibited hypertrophy in MSC-derived chondrocytes. When treated with 
ECM during the chondrogenic phase, hypertrophic differentiation and endochondral ossification 
were delayed, but not prevented. However, preservation of cartilage matrix was inferior when 
MSCs were treated ECM. Two strategies were designed to improve cartilage matrix preservation 
during hypertrophy, which includes either increasing the dose of ECM during chondrogenic 
phase, or increasing the culture duration of the chondrogenic phase. 
Analysis of bioactive components of the ECM in promoting MSC chondrogenesis 
revealed a role of collagen XI. Specifically, collagen XI promoted cartilage matrix formation in 
MSCs and human chondrocytes. It also inhibited degradation of cartilage matrix in human 
chondrocytes and bovine cartilage explants. 
Analysis of the signaling pathways of ECM regulation revealed potential involvement of 





effects of ECM. Furthermore, roxadustat, a small molecule Hif stabilizer, recapitulated the 
chondrogenic and anti-hypertrophic effects of cartilage ECM. In MSCs, healthy chondrocytes, 
and OA chondrocytes, roxadustat promoted cartilage matrix production and a hyaline phenotype. 
It also inhibited hypertrophy and matrix degradation.  
Overall, this work provides direct evidence of the role of cartilage ECM in maintaining 
cartilage homeostasis. We show that selectively promoting a hyaline phenotype was achievable 
in vitro and/or ex vivo by ECM or by Hif1α activation. The identified signaling pathways and 
ECM components may provide clues for therapeutic development in cartilage injury and 
degenerative disease. 
 This research is not without limitations. The decellularized cartilage ECM preserved 
some properties of native ECM, but the loss of some of the matrix materials and in particular 
GAG was significant. The digested ECM did not reproduce the structural and biomechanical 
functions of native ECM, either. Therefore, the observed effects in this work were likely one 
aspect of the physiological role of cartilage ECM. Secondly, we by no means fully identified all 
bioactive components in the ECM and only studied a few of the differentially activated/inhibited 
signaling pathways. Further discovery in ECM components and signaling is required. 
 The studies of Hif stabilizers provide a direction for future research in drug development. 
Despite the chondrogenic, anti-catabolic, and anti-hypertrophic effects of these molecules, their 
non-specific inhibition of collagen hydroxylation limits their use in cartilage diseases. Future 
research should aim to reduce their non-specific activities, which may enable the discovery of 





 Lastly, most of the experiments in this thesis have been replicated at least twice. However, 
the following experiments have only been conducted once and the results should be considered 
preliminary: the differential effects of the cartilage ECM during early, mid, and late 
chondrogenesis (Figure 13); the long-lasting effects of the cartilage ECM during early MSC 
chondrogenesis (Figure 14); the chondrogenic effects of ECM on MSCs in the presence of 
hydrogen peroxide and IL-1β (Figure 17); the transitory, but not permanent effects of ECM on 
mineralization of MSC pellets (Figure 20); the dose response of ECM and treatment duration of 
ECM during chondrogenic pre-culture on cartilage preservation at terminal hypertrophy (Figures 
21 and 22); the involvement of Hif1 signaling by ECM supplementation (Figure 24); the effects 
of roxadustat on the hyaline, non-hyaline, and cartilage maturity genes in MSCs (Figure 31); the 
effects of roxadustat on the hyaline and non-hyaline genes in healthy human chondrocytes 
(Figure 33); the effects of roxadustat on healthy and OA chondrocytes during hypertrophy 
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Appendix: List of Primers 
Species Gene For/Rev Sequence 
Human  b-actin for CTTCCAGCCTTCCTTCCTGG 
    rev CTGTGTTGGCGTACAGGTCT 
  Col2A1 for AGACTTGCGTCTACCCCAATC 
    rev GCAGGCGTAGGAAGGTCATC  
  Acan for CCCCTGCTATTTCATCGACCC  
    rev GACACACGGCTCCACTTGAT  
  COMP for CACTGACCTAGACGGCTTCC 
    rev CATCCTCCTGCCCTGAGTTG 
  Sox9 for AGCGAACGCACATCAAGAC 
    rev CTGTAGGCGATCTGTTGGGG 
  Col1A1 for GATCTGCGTCTGCGACAAC  
    rev GGCAGTTCTTGGTCTCGTCA 
  ALPL for GGGACTGGTACTCAGACAACG  
    rev GTAGGCGATGTCCTTACAGCC  
  BGLAP for GGCGCTACCTGTATCAATGG 
    rev GTGGTCAGCCAACTCGTCA  
  SPP1 for GTTTCGCAGACCTGACATCCA 
    rev GCTTTCCATGTGTGAGGTGAT 
  Runx2 for CCGTCTTCACAAATCCTCCCC 
    rev CCCGAGGTCCATCTACTGTAAC  
  IBSP for GAACCTCGTGGGGACAATTAC  
    rev CATCATAGCCATCGTAGCCTTG  
  SPARC for CCCAACCACGGCAATTTCCTA 
    rev CGTCTCGAAAGCGGTTCC 
  Col10A1 for CATAAAAGGCCCACTACCCAAC  
    rev ACCTTGCTCTCCTCTTACTGC  
  IHH for AACTCGCTGGCTATCTCGGT 
    rev GCCCTCATAATGCAGGGACT 
  PTHrP for GAGGGCAGATACCTAACTCAGG 
    rev CTGCTCTTTGTACGTCTCCAC 
  Col5A2 for GAAGGGAATGGCTGGAGGAC 
    rev CTGTATCTCCAGGGGTCCCA 
  Col5A1 for CTGGTGCAGTGGGAGAGAAG 
    rev CCCCTTTCTCCTTTGGGTCC 
  Col5A3 for CTGGTCCCATTGGCTCTCTG 
    rev CGGAGACCCTTTTGAGCCTT 
  Col6A2 for GGGTGAGCAGAACTTCCACA 
    rev CGTTGAGAGGGTCGTCGTC 
  Col6A3 for AGTGGTGGAAAGCCTGGATG 
    rev ACGACGTCCTGCTTGTTCAT 
  Col9A2 for AGGGCCTTCCTGGATTCTCT 





Species Gene For/Rev Sequence 
Human Col9A3 for ATCAGCGAACAAATTGCACAGT 
    rev CGCCAGGGTGACCAATGGA 
  Col12A1 for GTACACAGGACAGCGTTGGA 
    rev CTGGGACCTTTAGCACCAGG 
  Col15A1 for AGAGCTGCAGGACTGTTGTC 
    rev CTTGGCCCTTGAGGTTCACT 
  CSGALNACT1 for AATGAGCCTATCAGCAGGGC 
    rev GCCTATCTCCTCTCCTGCCT 
  Fibronectin1 for AGCCTGGGAGCTCTATTCCA 
    rev CTTGGTCGTACACCCAGCTT 
  BMPR2 for AGATCCTGGGCCATCAAAGC 
    rev TGCTGCCATCCAGGACATTT 
  Chondroadherin for AGAGGTCCAAGAAAGCTGGC 
    rev AGGCTGTGGGGAGAAGGTAT 
  HS3ST3A1 for TCTACCGGCCTTTCAACCTC 
    rev TATGGTTATCCATCCCAGCCA 
  HAPLN1 for TCATGAACGGGGCATGCAAT 
    rev TTGTGCTTGTGGAACCTGCT 
  CHRDL2 for CCCCTCTGAGCTTCATCCCT 
    rev TCCCCGTGGGAGTACGTCTT 
  Dlx5 for TACGCTAGCTCCTACCACCA 
    rev TTCACCATTCTCACCTCGGG 
  Nks3.2 for ACCGAGACGCAGGTGAAAAT 
    rev CACCTTTACGGCCACCTTCT 
  Fibromodulin for CGGTCACTGATCTTGCTGGA 
    rev AAGTAGCTATCGGGGACGGT 
  Biglycan for TCGATGGCCTGAAGCTCAAC 
    rev GGCTTCCTACCTTTGGGGAT 
  Decorin for TGGGTTTTAAGTGCAGGAAGGT 
    rev TCCCAATTTCTCTTGGCCCT 
  Epiphycan for CCGAAAACTGCCTCAACTTCG 
    rev AGTGGTTGGCAATTCTGGGA 
  Lumican for ATCTCACAACGAACTGGCTGA 
    rev CAGCTCAACCAGGGATGACA 
  Osterix for GCCATTCTGGGCTTGGGTAT 
    rev TGCAGGTATCAGGCACAAGG 
  PHD1 for GCTGGGCAGCTATGTCATCA 
    rev TCAACGTGCCTTACGTACCC 
  PHD2 for CGTCGCAACCCTCATGAAGTA 
    rev TCGTGCTCTCTCATCTGCATC 
  PHD3 for CACAGCGAGGGAATGAACCT 
    rev TCCTGCTGTTAAGGCTTCCG 
  Sox5 for CTCTGTCCCAGCAGCGTTAG 





Species Gene For/Rev Sequence 
Human Sox6 for CATGCCTCCCACCCACAAAT 
    rev GTAAGAGTGGCCACCACCAT 
  Mef2c for ATGTTGGGGCACATGTCCTG 
    rev CCTTCTTGTCTAGCACCCAGT 
  Zfp521 for ACAAATGGAGCTTCCGAGCA 
    rev CCATCGTGACTGTTGTGGGA 
  Sik3 for AGCACCGTACCAACCTGATG 
    rev GATGTGCACTGTGAGCCTCTG 
  Runx3 for ATTGGCCCACAGGATAAGCC 
    rev TGTAAATGCAGAGGGGGCTG 
  Hif1a  for TTTTACCATGCCCCAGATTCAGGA 
    rev ATCAGTGGTGGCAGTGGTAGTGGT 
  Hif2a for CCAGTCACCTTTCTCCACCC 
    rev GTGGTGAAGGTCCGAGGTG 
  MMP1 for CACAAACCCCAAAAGCGTGT 
    rev GCAGATCACAAAGAAGAACTGACA 
  MMP2 for CCTGCAAGTTTCCATTCCGC 
    rev CTTCTTGTCGCGGTCGTAGT 
  MMP3 for GTGGGCCCATCACCCATTA 
    rev GGAGGAAAACCTCATGGGCA 
  MMP13 for CCAGACTTCACGATGGCATTG 
    rev GGCATCTCCTCCATAATTTGGC 
  TIMP1 for ACACTGTTGGCTGTGAGGAAT 
    rev GTCCGTCCACAAGCAATGAG 
  TIMP2 for ATGTGACGCCAGCTAAGCAT 
    rev TGTCACCAAAGCCACCTACC 
  ADAMTS4 for GGAAATTCAGATGTGGTACTGCC 
    rev GCCACTAGGACTTGCAGTGT 
  ADAMTS5 for AGTAATTCCGTCTGCGTCCG 
    rev TCTCCTCCACATACTCCGCA 
 
 
Species  Gene For/Rev Sequence 
Bovine  b-actin for CGCACCACTGGCATTGTCAT 
     rev TCCAAGGCGACGTAGCAGAG 
   Acan for AGTAAGGGCCACTGCATTCC 
     rev GTGGACTCTCTGGGAAAGGC 
   Sox9 for GATGACCGACGAGCAGGAGAA 
     rev GCAGAGTCCTCGGACATGGTG 
   Col2A1 for GAAGGGAGAAGTTGGACCCC 
     rev CTGTCTCTCCACGTTCACCC 
   Col1A1 for AAGGTATTGCTGGACAGCGT 





Species  Gene For/Rev Sequence 
Bovine  Col9A1 for GTGGTGAAGAAGGGGACCAG 
     rev CGGTGATGCCTCTCAAACCT 
   Fibromodulin for AAGCGACCTGATGTTGCGTA 
     rev GCCTCCTCAGTTCAGCCAAT 
   HAPLN1 for CTGGGATATGACCGTTGCGA 
     rev TGTCTGGGAAACCCACGAAG 
   COMP for ACCCAGACCAGCGAAATACG 
     rev CTCGGCCGTCCTTATCTGTG 
   Fibronectin1 for ACCACACGAAACTGGTGGTT 
     rev GCTTGCAGGTCCATTCTCCT 
   Chondroadherin for GCCTTCTGCCGGAGAAACTA 
     rev ATCAGCAGAGGGTGTTGGGA 
   FRZB for CATCAAGTACCGCCACTCGT 
     rev TAGGAAAATCGGCTCCGTCG 
   HS3ST3A1 for TCATCGGTGTGAAGAAGGGC 
     rev GTAGCTGCGGTCGAAGAAGT 
   Col5A1 for CGGATGTCGCCTACAGAGTC 
     rev AAACGCAGATGCAGGGTACA 
   Col5A2 for CCCAGTGGGAGAAAGGGGTAT 
     rev CCCCCTGACCTCCTTTAGGT 
   Col6A1 for CTGAGAGCATCGGCCTACAG 
     rev GACCAGCTCATCCTTGCTCA 
   Col6A2 for GAGATCGTGGTTTGCCTGGA 
     rev TCTCCCCGAGATCCCTGTTT 
   Col6A3 for CCGGGAAGTCGGATGATGAG 
     rev TCAGCGAGATCTTCACCAGC 
   Col12A1 for GAATCTGCTGGGGCAAGAGT 
     rev CGTCCTGGGATTTGCCATCT 
   Col15A1 for GCCCCTCCGGTAAGTGAAGA 
     rev CCTCAGCTTCACCCTTCTCG 
   MMP1 for TCTCAAGAGAGGAAGAGACGAGA 
     rev GGATGGTAGTGGTGGTTGCT 
   MMP3 for TCTCCAGCACTCAACCGAAC 
     rev GGAACCGAGTGAGGTCTGTG 
   MMP13 for ATGCCATAACCAGTCTCCGC 
     rev CTGCTTCAACCTGCTGAGGA 
 
